Balyasny Asset Management LLC Phathom Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 65,659 shares of PHAT stock, worth $456,986. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,659
Previous 15,006
337.55%
Holding current value
$456,986
Previous $154,000
670.78%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PHAT
# of Institutions
143Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$70.4 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$52 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$40.8 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$28.5 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$24.3 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $273M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...